Navigation Links
JCM Passes Internal Quality Assessment for Azithromycin API Production
Date:11/9/2011

degradation products of Azithromycin as well as intermediate compounds of the semi-synthesis may be present as well. The detection and assessment of the purity of the Azithromycin sample become the key element for quality control.

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and active pharmaceutical ingredients (API). TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

For more information about TPI, please visit:  http://www.tianyinpharma.com

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit: http://www.tianyinpharma.com, or email: ir@tpi.asia

Tel: +86-28-8551-6696 (Chengdu, China)
+86-134-3655-0011 (China)
Address:
Tianyin Pharmaceutical Inc.
23rd Floor, Unionsun Yangkuo
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Simceres Branded Generic Formulation Biqi Passes EU-GMP Inspection
2. German Patient Surpasses 5 Years of Support on DuraHeart™ Left Ventricular Assist Device
3. Acumen nEHR Surpasses 1,000 Nephrology Providers
4. Use of TIGR® Matrix Surgical Mesh in Multi-Center Randomized Controlled TRAM Flap Study Passes 20 Patient Mark and Wins Praise from Participating Surgeons
5. Netsmart Technologies Insight Public Health Software Passes ARRA Certification Tests
6. Caliper Life Sciences IVIS® Optical Imaging System Adoption Surpasses 1000 Units: Validated Drug Research, Discovery and Development Tool Enables Advances in Personalized Medicine
7. STAAR Surgicals Visian® ICL Surpasses 200,000 Implants
8. Lilly Surpasses United Way 2010 Campaign Goal
9. Health Robotics Surpasses 100 Installations Milestone and Acquires Two I.V. Room of the Future Partner Companies
10. Simceres Diosmectite API Passes EU-GMP Inspection
11. Osteotechs MagniFuse(TM) Distributed to 68 U.S. Hospitals as Product Revenue Surpasses $1 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... August 3, 2015 ... companies, military surgical research and top-tier universities ... regards to severe wound treatments for critical-care ... regenerative medicine and tissue-engineered skin substitute advancements.  ... advancements in focus are Amarantus Bioscience Holdings, ...
(Date:8/3/2015)... , Aug. 3, 2015 Biosensors International ... SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer ... financial results for its first fiscal quarter ended ... Quarter Highlights and Recent Developments: ... improving its cost structure, driven by lower operating ...
(Date:8/3/2015)... 2015  Array BioPharma Inc. (NASDAQ: ARRY ... and full year of its fiscal year ended ... Executive Officer of Array, noted, "Binimetinib and encorafenib, two ... track for regulatory submissions in 2016. Additional data ... BRAF-mutant colorectal cancer further validate the value of ...
Breaking Medicine Technology:Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12
... 16, 2011 Two Colorado women, Laura Smallen and ... aid industry through an innovative company called Hearing Care ... are simply too expensive and have designed a business ... with hearing aid manufacturers, health plans and patients for ...
... U.S. Marshals, at the request of the U.S. ... of Auralgan Otic Solution, a prescription drug used ... infections, from Integrated Commercialization Solutions Inc. (ICS) in ... located in Chapel Hill, N.C., and is warehoused ...
Cached Medicine Technology:Hearing Healthcare Reform 2U.S. Marshals Seize Auralgan Otic Solution 2
(Date:8/3/2015)... ... ... opinion piece published July 28 by the Washington Post, the conventional wisdom that ... not be accurate. While this system may work for some people, the author notes that ... on the individual and at what point that person is in their weight loss journey. ...
(Date:8/3/2015)... ... , ... Bayer has agreed to pay $56.9 million to set up a ... to have suffered an arterial blood clot including stroke and heart attack. The litigation ... has been ongoing for well-over five years. In 2009, lawsuits filed against Bayer involving ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... finalist in 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb ... for B2B brands. BESLER Consulting's campaign for the launch of their Readmissions Analytics ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... contract research organisations (CROs) for a slew of benefits, allowing them to gain ... operations, boost quality with cost-effective utilisation of resources, get access to innovation and ...
(Date:8/3/2015)... ... 2015 , ... A recent survey by the National ... believe people can positively affect their diabetes, few look beyond diet changes to ... changes was important. Far fewer participants mentioned the need for exercise (30%), maintaining ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4
... for Provider Profiling, Predictive Modeling, Resource Management and ... DST Health Solutions today announced the ... DSTHS RiskAnalyzer(TM). RiskAnalyzer uses claims experience to determine ... under the Centers for Medicare and Medicaid Services ...
... QHR hospital clients received unexpected checks totaling nearly ... ranging from $65,000 to more than $750,000 - ... a unique and innovative partnership between the hospital ... Under the QHR/Gallagher Retro Insurance Program, hospital groups ...
... cadherin superfamily has a correlate relationship with the ... suggested that, unlike E-cadherin, N-cadherin may promote motility ... pathological significance of E-cadherin and N-cadherin expressions in ... led by Prof. Qing-Xia Fan from China detected ...
... 100,000 Swedes are under treatment with the blood-thinning drug ... makes the initiation of treatment a risky balancing act ... Uppsala University have developed a model for calculating the ... in the scientific publication New England Journal of ...
... PURCHASE, N.Y., Feb. 19 The PepsiCo Foundation ... Save the Children to help ensure the survival ... and Bangladesh, which together are home to 40 ... )With support from the PepsiCo Foundation, Save ...
... 19 Cardium Therapeutics (NYSE Alternext US: CXM) ... on January 23, 2009 has been accepted by ... Stock Exchange). (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO )As ... from the staff of its current listing exchange ...
Cached Medicine News:Health News:DST Health Solutions Launches New RiskAnalyzer Software to Help Medicare Advantage Plans Manage Risk Adjustment 2Health News:DST Health Solutions Launches New RiskAnalyzer Software to Help Medicare Advantage Plans Manage Risk Adjustment 3Health News:QHR, Gallagher Partnership Yields More Thank $4 Million for QHR Hospital Clients 2Health News:Knowledge of genetics improves uncertain medication 2Health News:PepsiCo Foundation Announces Grant to Save the Children to Address Malnutrition in Developing Nations 2Health News:PepsiCo Foundation Announces Grant to Save the Children to Address Malnutrition in Developing Nations 3Health News:Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext US 2Health News:Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext US 3Health News:Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext US 4Health News:Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext US 5
... use, the z-boxTM is designed to bring ... business model behind the z-boxTM is designed ... most flexible way to bring this technology ... to run procedure specific software in many ...
NOW Legionella is an immunochromatographic membrane assay to detect Legionella pneumophila serogroup 1 soluble antigen in human urine....
ThyroTest TSH is a rapid, qualitative test for hypothyroidism screening in adults....
... The BinaxNOW Influenza A & B ... easiest flu test on the market ... between influenza A and influenza B ... test. Now you can focus on ...
Medicine Products: